Stoke and Biogen report four-year zorevunersen data showing durable Dravet seizure reductions
Stoke Therapeutics and Biogen say four-year zorevunersen data show durable seizure reductions plus continuing cognitive and behavioral improvements as Phase 3 EMPEROR advances.